High dose intravenous immunoglobulin (IVIG) in dermatomyositis: Clinical responses and effect on sIL-2R levels

European Journal of Dermatology

Volumn 10, Issue 1, 2000, Pages 29-35

  Göttfried, Isolde ^a   Seeber, Arno ^a   Anegg, Barbara ^a   Rieger, Armin ^a   Stingl, Georg ^a   Volc Platzer, Beatrix ^a  

^a Donauspital ^*

Author keywords

Dermatomyositis; Intravenous immunoglobulin; IVIG; sIL 2R

Indexed keywords

AZATHIOPRINE; CD8 ANTIGEN; CHLOROQUINE; CREATINE KINASE; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; IMMUNOGLOBULIN 7S; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ACTIVITY; DOSE TIME EFFECT RELATION; DRUG COST; ELECTROMYOGRAM; FEMALE; HEADACHE; HUMAN; HUMAN CELL; MALE; RECTUM CANCER; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD8; AUTOANTIBODIES; CREATINE KINASE; DERMATOMYOSITIS; ELECTROMYOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MALE; MIDDLE AGED; PARANEOPLASTIC SYNDROMES; RECEPTORS, INTERLEUKIN-2; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0007752117     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. 1. Cherin P, Herson S, Wechsler B, Piette JP, Bletry O, Coutellier A, Ziza A, Godeau P. Efficacy of intravenous gammaglobulin therapy in chronic refractory PM and dermatomyositis: an open study with 20 patients. Am J Med 1991; 91: 162-7.
2. 2. Hanslik T, Jaccard A, Guillon JM, Vernant JP, Wechsler B, Godeau P. PM and chronic graft-versus-host disease: efficacy of intravenous gamma-qlobulin. J Am Acad Dermatol 1993; 28: 492-3.
3. 3. Jann S, Beretta S, Moggio M, Adobbati L, Pellegrini G. High dose intravenous human immunglobulin in PM resistant to treatment. J Neurol Neurosurg 1992; 55: 60-2.
4. 4. Lang B, Laxer RM, Murphy G, Silverman ED, Roifman C. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91:169-72.
5. 5. Roifman CM, Schaffer FM, Wachsmuth SE. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 1987; 258: 513-5.
6. 6. Zifko U, Grisold W. Dermatomyositis: Erfolgreiche Therapie mit hochdosierten intravenös applizierten 7S-Immunglobulinen. Wien klin Wochenschr 1995; 107: 522-4.
7. 7. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000.
8. 8. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107-15.
9. 9. Manchul LA, Jin A, Pritchard KI, Tenenbaum J, Boyd NF, Lee P, Germanson T, Gordon DA. The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. Arch Int Med 1985; 145: 1835-9.
10. 10. Targoff IN. Humoral immunity in PM/dermatomyositis. J Invest Dermatol 1993; 100: 116s-23s.
11. 11. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogenous patient groups. Medicine 1991; 70: 360-74.
12. 12. Miller FW, Love LA Barbieri SA, Balow JE, Plotz PH. Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. Clin Exp Immunol 1990; 81: 373-9.
13. 13. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344-7.
14. 14. Cherin P, Herson S, Wechsler B, Bletry O, Degennes C, Piette JC, Ziza JM, Godeau P. Intravenous immunoglobulin for polymyositis and dermatomyositis. Lancet 1990; ii: 116.
15. 15. Imbach P, d'Apuzzo V, Hirt A, Rossi E, Vest M, Baranduin S, Baumgartner C, Morell A, Schöni M, Wagner HP. High-dose intravenous gammoglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; i: 1228-31.
16. 16. Geha RS, Rosen FS. Intravenous immunoglobulin therapy. In: Austen KF, Burakoff SJ, Rosen FS, Strom TB, eds. Therapeutic Immunology. Cambridge, Mass.: Blackwell Science, 1996: 280-96.
17. 17. Geha RS. Regulation of the immune response by idiotypic-antiidiotypic interactions. N Engl J Med 1981; 305: 25-8.
18. 18. Lam L, Whitsett CF, McNicholl JM, Hodge TW, Hooper J. Immunologically active proteins in intravenous immunoglobulin. Lancet 1993; ii: 678.
19. 19. Achiron A, Margalit R, Hershkoviz, Markovits, Reshef T, Melamed E, Cohen IR, Lider O. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. J Clin Invest 1994; 93: 600-5.
20. 20. Stohl W. Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J Immunol 1986; 136: 4407-13.
21. 21. Kondo N, Kasahara K, Kameyama T. Intravenous immunoglobulins suppress immunoglobulin production by suppressing calcium-dependent signal transduction through Fc gamma receptors in B lymphocytes. Scand J Immunol 1994; 40: 37-42.
22. 22. Andersson UG, Björk L, Skansen-Saphir JP, Andersson JP. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunol 1993; 79: 211-6.
23. 23. Toyoda M, Zhang X, Petrosian A, Galera O, Wang SJ, Jordan SC. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994; 14: 178-89.
24. 24. Basta M, Fries LF, Frank MM. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991; 77: 376-80.
25. 25. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3.
26. 26. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227-8.
27. 27. Ghetie V, Ward ES. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 1997; 18: 592-8.
28. 28. Kroll M, Otis J, Kagen L. Serum enzymes, myoglobin and muscle strength relationship in polymyositis and dermatomyositis. J Rheumatol 1986; 13: 349-55.
29. 29. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis). J Am Acad Dermatol 1991; 24: 959-66.
30. 30. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993; 43: 876-9.
31. 31. Mastaglia FL, Phillips BA, Zilko P. Treatment of inflammatory myopathies. Muscle & Nerve 1997; 20: 651-64.
32. 32. Symons JA, Wood NC, Di Giovine FS, Duff GW. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol 1988; 141: 2612-8.
33. 33. Manoussakis MN, Papadopoulos GK, Drosos AA, Moutsopoulos HM. Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol 1989; 50: 321-32.
34. 34. Famularo G. Procopio A, Giacomelli R, et al. Soluble interleukin-2 receptor, interleukin-2, and interleukin 4 in sera and supernatants from patients with progressive systemic sclerosis. Clin Exp Immunol 1990; 81: 368-72.
35. 35. Kroemer G, Martinez AC. Cytokines and autoimmune disease. Clin Immunol Immunopathol 1991; 61: 275-95.
36. 36. Wolf RE, Brelsford WG. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 1988; 31: 729-35.
37. 37. Steiner G, Studnicka-Benke A, Witzmann G, Höfler E, Smolen J. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J Rheumatol 1995; 22: 406-12.
38. 38. Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska Jr. K. Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. Arthritis Rheum 1990; 33: 375-80.
39. 39. Barron KS, Montalvo JF, Joseph AK, Hilario MO, Saadeh C, Giannini EH, Orson FM. Soluble interleukin-2 receptors in children with Kawasaki syndrome. Arthritis Rheum 1990; 33: 1371-7.
40. 40. Wolf RE, Baethige BA. Inteleukin-1a, interleukin-2, and soluble interleukin-2 receptors in polymyositis. Arthritis Rheum 1990; 33: 1007-14.
41. 41. Seth R, Raymond FD, Makgoba MW. Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet 1991; 338: 83-4.
42. 42. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA, et al. Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995; 273: 457-92.
43. 43. Jolles S, Hughes J, Whittacker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998; 134: 80-6.